Atrium Therapeutics, Inc. (RNA) Institutional Ownership & Insider Trading
155 institutions reported holding Atrium Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 21 insider trades on Form 4 since 2025-10-01.
Source: SEC EDGAR filings · read by EquiReason
RNAAtrium Therapeutics, Inc.Follow RNA — free
—
Price chart with a free account
- Market cap
- 140.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Institutions · all 13F filers
quarter to 30 Jun 2026 · filers in both quarters155 institutions held 90.6% of the shares. Across filers that reported both quarters, shares held changed +11.6%.
Largest moves, shares (millions)
Institutional flow by quarter
net shares added or trimmed, millions · filers in both quarters| Quarter | Holders | Shares held, M | Change | Increased | New | Decreased | Closed |
|---|---|---|---|---|---|---|---|
| Jun 26 | 155 | 15 | +11.6% | 45 | 34 | 35 | 38 |
| Mar 26 | 160 | 15 | — | — | — | — | — |
Atrium Therapeutics, Inc. — questions
- Who owns Atrium Therapeutics, Inc. stock?
- 155 institutions reported Atrium Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: Sessa Capital IM, L.P. (8.8%), PRICE T ROWE ASSOCIATES INC /MD/ (8.6%), BlackRock, Inc. (8.5%).
- Are Atrium Therapeutics, Inc. insiders buying or selling?
- 21 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.
Every figure on this page comes from Atrium Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.